Canadian drug-device developer Interface raises funds
This article was originally published in Clinica
Interface Biologics, a spin-out from the University of Toronto, Canada, has closed its first venture capital financing, raising Can$10m (US$8.2m). It will use the proceeds to fund ongoing biomaterial development programmes, and to support corporate partnerships.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.